vimarsana.com

அல்லாத மது கொழுப்பு கல்லீரல் நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mitotherapeutix Awarded $2 2 Million SBIR Grant from the National Institutes of Health for siRNA NASH Candidates

Mitotherapeutix Awarded $2.2 Million SBIR Grant from the National Institutes of Health for siRNA NASH Candidates Share Article FARMINGTON, Conn. (PRWEB) June 04, 2021 Mitotherapeutix LLC (MITO), a pre-clinical stage company focused on siRNA drug discovery and development based on suppression of the mitochondrial regulator MCJ (DnaJC15), today announced that it has been awarded a multi-year $2.2 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health. MITO will deploy the funds to continue IND enabling activities for siRNA candidates intended to be a novel treatment for Nonalcoholic Steatohepatitis (NASH). “NASH remains a significant unmet medical need affecting up to 5% of all adults in the United States, according to the Liver Foundation,” said Jack Talley, Chief Executive Officer, MITO. “Our novel GalNAc conjugated-siRNA candidates are being advanced towards IND fili

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.